High rate of early cancer recurrence following direct-acting antiviral treatment for hep C virus

A new study has shown that patients with a prior history of hepatocellular carcinoma and who have been treated with direct-acting antivirals for Hepatitis C infection have a higher than expected early recurrence rate of their liver cancer than previously thought — with the rate in some subgroups exceeding 40 percent.